- Conditions
- Head and Neck Cancer
- Interventions
- Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 14
- States / cities
- Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 112
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Small Cell Lung Cancer
- Interventions
- Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- ampreloxetine
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer
- Interventions
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
- Biological · Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, Enzalutamide, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more
- Conditions
- Parkinson Disease
- Interventions
- Safinamide
- Drug
- Lead sponsor
- Newron Pharmaceuticals SPA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Parkinson Disease
- Interventions
- Stimulation
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 22 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Parkinson Disease
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 30 participants
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
- Drug · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 907 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
- Conditions
- Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
- Interventions
- Pembrolizumab, Paclitaxel, Bevacizumab, Placebo for pembrolizumab, Docetaxel
- Biological · Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Greenbrae, California • Monterey, California + 28 more
- Conditions
- Biliary Tract Carcinoma
- Interventions
- Pembrolizumab, Gemcitabine, Cisplatin, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,069 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more
- Conditions
- Endometrial Neoplasms
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer
- Interventions
- Pembrolizumab, Lenvatinib, Docetaxel
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 28
- States / cities
- Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more
- Conditions
- Parkinson Disease
- Interventions
- Tavapadon, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 24 more
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
- Interventions
- Dipraglurant, Placebo
- Drug
- Lead sponsor
- Addex Pharma S.A.
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Fresno, California • Irvine, California + 38 more
- Conditions
- Parkinson Disease
- Interventions
- Isradipine, Placebo (for Isradipine)
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Istradefylline 40 mg, Istradefylline 20 mg, Placebo
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
- Conditions
- Parkinson Disease
- Interventions
- BHV-8000 10mg, BHV-8000 20 mg, Placebo
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Farmington, Connecticut + 12 more
- Conditions
- Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
- Interventions
- favezelimab/pembrolizumab, pembrolizumab, lenvatinib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • New Brunswick, New Jersey + 5 more
- Conditions
- Melanoma
- Interventions
- Pembrolizumab/Vibostolimab, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 30
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 22 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Istradefylline 20 mg or 40 mg
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 20 more
- Conditions
- Parkinson's Disease
- Interventions
- Accordion Pill™ Carbidopa/Levodopa, Sinemet®, Placebo -AP-CD/LD, Placebo- Sinemet
- Drug
- Lead sponsor
- Intec Pharma Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more
- Conditions
- Parkinson's Disease and Parkinsonism
- Interventions
- DBS
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota